Big Pharma Fined $3.75 Billion in Fraud Penalties in Fiscal 2013

According to the U.S. Departments of Justice and Health and Human Services, these departments recovered $4.3 billion in criminal and civil fines in the 2013 fiscal year, which ended in September 2013.  This is a $100 million increase from the 2012 fiscal year.  The five-year total in fines has now reached $19.2 billion.  Pharma drugmakers [...]

March 3rd, 2014|Drug and Medical Device Litigation|Comments Off on Big Pharma Fined $3.75 Billion in Fraud Penalties in Fiscal 2013

Endo Health Solutions Saving $520 Million to Fund Transvaginal Mesh Lawsuits While Settling Off Label Marketing Claims for Lidoderm

In 2011, Endo Health Solutions bought American Medical Systems, one of the manufacturers who is currently embroiled in the transvaginal mesh litigation, with over 5,000 pending lawsuits before Judge Joseph Goodwin.  In 2008, women who used these devices began filing suits against American Medical Systems.  In 2013, Endo agreed to pay some $54.5 million toward [...]

February 26th, 2014|Drug and Medical Device Litigation, Transvaginal Mesh|Comments Off on Endo Health Solutions Saving $520 Million to Fund Transvaginal Mesh Lawsuits While Settling Off Label Marketing Claims for Lidoderm

A Brief Review of The Trial Testimony and Directed Verdict for Ethicon in Carolyn Lewis Mesh Bellwether Case

On February 18, 2014, Judge Joseph Goodwin granted Ethicon’s Motion for Directed Verdict at the close of Plaintiff’s case in Lewis vs. Ethicon, Inc. (In Re:  Ethicon, Inc., Pelvic Repair System Products Liability Litigation, MDL Docket No. 2327, Carolyn Lewis, et al. v. Johnson & Johnson, et al., No. 2:12-4301, S.D. W.Va.). What is a [...]

February 19th, 2014|Drug and Medical Device Litigation, Transvaginal Mesh|Comments Off on A Brief Review of The Trial Testimony and Directed Verdict for Ethicon in Carolyn Lewis Mesh Bellwether Case

Big Pharma: Is Paying Big Fines More Profitable than Telling Doctors and Consumers the Truth in Marketing?

This week, Johnson & Johnson etched its name in the history books of another big pharma company that has been fined over billions of dollars due to a drug manufacturer practices of improper marketing and failure to warn.  Johnson & Johnson pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed [...]

November 7th, 2013|Actos Diabetes Drug, Avandia Diabetes Drug, DePuy Hip Replacement, Drug and Medical Device Litigation, Fosamax Osteoporosis Drug, Lipitor, Transvaginal Mesh|Comments Off on Big Pharma: Is Paying Big Fines More Profitable than Telling Doctors and Consumers the Truth in Marketing?

Johnson & Johnson Pleads Guilty to Criminal Charges and is Fined $2.2 Billion for Improperly Marketing Risperdal

Janssen Pharmaceuticals, Inc. (JPI), a Johnson and Johnson company, has pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed the anti-psychotic drug Risperdal for inappropriate uses and paid kickbacks to doctors and nursing homes in prescribing the drug.  JPI will plead guilty to one misdemeanor violation of the Food Drug [...]

November 5th, 2013|Drug and Medical Device Litigation|Comments Off on Johnson & Johnson Pleads Guilty to Criminal Charges and is Fined $2.2 Billion for Improperly Marketing Risperdal

United Kingdom Seeks to Eliminate the Use of Metal-on-Metal Implants Due to High Failure Rate

Because of the high failure rates of metal on metal hip devices, and the potential for toxic exposure, the United Kingdom is moving to ban all metal-on-metal hip replacements performed at National Health Service [NHS] hospitals.  NHS is the publicly funded health care system in the U.K, the NHS seeks to stop these surgeries with [...]

November 1st, 2013|DePuy Hip Replacement, Drug and Medical Device Litigation|Comments Off on United Kingdom Seeks to Eliminate the Use of Metal-on-Metal Implants Due to High Failure Rate

Cisson Verdict Upheld by Trial Court

According to a report in Fierce Medical Devices, the trial court has upheld the 2 million verdict in the Donna Cisson v. C.R. Bard, Inc. transvaginal trial.  Judge Joseph Goodwin reaffirmed that the initial award was appropriate and that attorneys representing Donna Cisson successfully proved the company's vaginal mesh was the cause of her injuries. [...]

October 30th, 2013|Drug and Medical Device Litigation, Transvaginal Mesh|Comments Off on Cisson Verdict Upheld by Trial Court

Drugs, Advertising, and Risks Associated with Direct to Consumer Ads

If you have watched a news program, sporting event, or network television show recently you have seen multiple ads for drugs or devices that will change your life.  Whether it is “Larry the cable guy” for the “purple” pill, a handsome athletic looking couple looking for the right moment assisted by a “blue” pill, an [...]

October 23rd, 2013|Drug and Medical Device Litigation|Comments Off on Drugs, Advertising, and Risks Associated with Direct to Consumer Ads

Bloomberg Reports Settlement Talks in Mesh Cases

Bloomberg is reporting that C.R. Bard, Endo Health Solutions, Boston Scientific, Cook, and Coloplast are in what Judge Goodwin described a “behind the scenes” settlement talks.  Johnson and Johnson (J&J) is reportedly NOT participating. Bard was held liable in two jury verdicts so far.  In July 2012, Bard lost an Avaulta case in a California [...]

September 30th, 2013|Drug and Medical Device Litigation, Transvaginal Mesh|Comments Off on Bloomberg Reports Settlement Talks in Mesh Cases

Boston Scientific Vaginal Mesh Bellwether Cases Trials Scheduled

On August 29, 2013, Judge Joseph Goodwin announced the bellwether case schedule for the Boston Scientific vaginal mesh cases occurring in West Virginia.  The following cases were selected for the first and second bellwether trials in this MDL: Carol Lynn Fawcett, et al. v. Boston Scientific Corp. 2:12-cv-07497 Pinnacle Roseanne Sanchez, et al. v. Boston [...]

August 30th, 2013|Drug and Medical Device Litigation, Transvaginal Mesh|Comments Off on Boston Scientific Vaginal Mesh Bellwether Cases Trials Scheduled